(Q28251391)

https://api.crossref.org/works/10.3810/PGM.2014.11.2828

A prospective study of triglyceride level, low-density lipoprotein particle diameter, and risk of myocardial infarction

21 April 2017

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2014.11.2828

Triglyceride concentration and ischemic heart disease: an eight-year follow-up in the Copenhagen Male Study.

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2014.11.2828

Triglycerides and cardiovascular disease: a scientific statement from the American Heart Association

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2014.11.2828

Evaluation and treatment of hypertriglyceridemia: an Endocrine Society clinical practice guideline

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2014.11.2828

30-year trends in serum lipids among United States adults: results from the National Health and Nutrition Examination Surveys II, III, and 1999-2006.

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2014.11.2828

Hypertriglyceridemia and its pharmacologic treatment among US adults

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2014.11.2828

2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2014.11.2828

Effects of omega-3 fatty acids on serum markers of cardiovascular disease risk: a systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2014.11.2828

n-3 Fatty acids and cardiovascular disease: evidence explained and mechanisms explored

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2014.11.2828

Long chain omega-3 fatty acids and cardiovascular disease: a systematic review.

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2014.11.2828

Fish consumption, fish oil, omega-3 fatty acids, and cardiovascular disease

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2014.11.2828

Omega-3 polyunsaturated fatty acids and cardiovascular diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2014.11.2828

Long-chain omega-3 fatty acids eicosapentaenoic acid and docosahexaenoic acid and blood pressure: a meta-analysis of randomized controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2014.11.2828

Dietary supplementation with n-3 polyunsaturated fatty acids and vitamin E after myocardial infarction: results of the GISSI-Prevenzione trial. Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto miocardico

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2014.11.2828

Effect of n-3 polyunsaturated fatty acids in patients with chronic heart failure (the GISSI-HF trial): a randomised, double-blind, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2014.11.2828

n-3 fatty acids and cardiovascular events after myocardial infarction

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2014.11.2828

n-3 fatty acids and cardiovascular outcomes in patients with dysglycemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2014.11.2828

OMEGA, a randomized, placebo-controlled trial to test the effect of highly purified omega-3 fatty acids on top of modern guideline-adjusted therapy after myocardial infarction

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2014.11.2828

Effects of eicosapentaenoic acid on major coronary events in hypercholesterolaemic patients (JELIS): a randomised open-label, blinded endpoint analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2014.11.2828

Effects of EPA on coronary artery disease in hypercholesterolemic patients with multiple risk factors: sub-analysis of primary prevention cases from the Japan EPA Lipid Intervention Study (JELIS).

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2014.11.2828

Fish oil and postoperative atrial fibrillation: the Omega-3 Fatty Acids for Prevention of Post-operative Atrial Fibrillation (OPERA) randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2014.11.2828

n-3 fatty acids in patients with multiple cardiovascular risk factors

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2014.11.2828

Omega-3 free fatty acids for the treatment of severe hypertriglyceridemia: the EpanoVa fOr Lowering Very high triglyceridEs (EVOLVE) trial

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2014.11.2828

Steady-state bioavailability of prescription omega-3 on a low-fat diet is significantly improved with a free fatty acid formulation compared with an ethyl ester formulation: the ECLIPSE II study

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2014.11.2828

Why do omega-3 fatty acids lower serum triglycerides?

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2014.11.2828

Prescription omega-3 fatty acids and their lipid effects: physiologic mechanisms of action and clinical implications

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2014.11.2828

Correlation of serum triglyceride and its reduction by omega-3 fatty acids with lipid transfer activity and the neutral lipid compositions of high-density and low-density lipoproteins.

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2014.11.2828

Eicosapentaenoic acid ethyl ester (AMR101) therapy in patients with very high triglyceride levels (from the Multi-center, plAcebo-controlled, Randomized, double-blINd, 12-week study with an open-label Extension [MARINE] trial).

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2014.11.2828

Efficacy and tolerability of adding prescription omega-3 fatty acids 4 g/d to simvastatin 40 mg/d in hypertriglyceridemic patients: an 8-week, randomized, double-blind, placebo-controlled study.

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2014.11.2828

A highly bioavailable omega-3 free fatty acid formulation improves the cardiovascular risk profile in high-risk, statin-treated patients with residual hypertriglyceridemia (the ESPRIT trial).

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2014.11.2828

Effects of eicosapentaenoic acid and docosahexaenoic acid on low-density lipoprotein cholesterol and other lipids: a review

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2014.11.2828

Effects of eicosapentaenoic acid versus docosahexaenoic acid on serum lipids: a systematic review and meta-analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2014.11.2828

Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2014.11.2828

Distinct regulation of plasma LDL cholesterol by eicosapentaenoic acid and docosahexaenoic acid in high fat diet-fed hamsters: participation of cholesterol ester transfer protein and LDL receptor.

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2014.11.2828

National Lipid Association recommendations for patient-centered management of dyslipidemia: part 1 - executive summary

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2014.11.2828

Potential benefits of icosapent ethyl on the lipid profile: case studies

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2014.11.2828

A retrospective case series of the lipid effects of switching from omega-3 fatty acid ethyl esters to icosapent ethyl in hyperlipidemic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2014.11.2828

Atherosclerosis: current pathogenesis and therapeutic options

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2014.11.2828

Eicosapentaenoic acid (EPA) from highly concentrated n-3 fatty acid ethyl esters is incorporated into advanced atherosclerotic plaques and higher plaque EPA is associated with decreased plaque inflammation and increased stability.

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2014.11.2828

Icosapent ethyl, a pure ethyl ester of eicosapentaenoic acid: effects on circulating markers of inflammation from the MARINE and ANCHOR studies

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2014.11.2828

Long chain omega-3 dietary supplements: a review of the National Library of Medicine Herbal Supplement Database

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2014.11.2828

Dietary sources of omega 3 fatty acids: public health risks and benefits

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2014.11.2828

Update on marine omega-3 fatty acids: management of dyslipidemia and current omega-3 treatment options

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2014.11.2828

Fish oil for the treatment of cardiovascular disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2014.11.2828

Long-chain omega-3 polyunsaturated fatty acids and risk of stroke: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2014.11.2828

21 January 2018

Identifiers

DOI

10.3810/PGM.2014.11.2828

1 reference

Consolidated OpenCitations Corpus – April 2017

22343

22343

1 reference

Consolidated OpenCitations Corpus – April 2017

Consolidated OpenCitations Corpus – April 2017

1 reference